Results 31 to 40 of about 5,807 (256)

Health‐Related Social Needs in Children With Sickle Cell Disease Are Associated With Worse Health‐Related Quality of Life

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with sickle cell disease (SCD) face multiple acute and chronic medical complications that may impact their quality of life as reported by patients themselves. Health‐related social needs (HRSNs), such as food and housing insecurity, are common in people with SCD, but the association between HRSNs and patient‐reported ...
Sarah J. Marks, Molly Sonenklar, Cerelia Donald, Cecelia Valrie, Wally Smith, India Sisler   +5 more
wiley   +1 more source

DARPin-fused T cell engager for adenovirus-mediated cancer therapy

Molecular Therapy: Oncology
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome.
Patrick C. Freitag, Jonas Kolibius, Ronja Wieboldt, Remi Weber, K. Patricia Hartmann, Merel van Gogh, Dominik Brücher, Heinz Läubli, Andreas Plückthun   +8 more
doaj   +1 more source

Feasibility and Safety of Somato‐Cognitive Coordination Therapy for Cerebellar Ataxia Following Pediatric Brain Tumor Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cerebellar ataxia after pediatric brain tumor treatment can cause persistent gait, balance, and speech impairment, yet no established rehabilitation strategy exists. Somato‐cognitive coordination therapy (SCCT) is a virtual reality–guided intervention designed to promote sensorimotor integration through visually constrained reaching
Masanobu Takeuchi, Takashi Matsuzawa, Jun Yamanishi, Masahiro Yoshitomi, Junji Ikeda, Shin‐Ichi Tsujimoto, Yasuteru Yamaguchi, Norio Shiba, Dhroov Pathare, Ayumi Kato, Masahiko Hara   +10 more
wiley   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science
T cell receptor (TCR) based immunotherapy is an attractive strategy to target a wide range of intra‐tumoral antigens and elicit robust tumor cytotoxicity.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
doaj   +1 more source

Elranatamab: A novel B-cell maturation T-cell engager

Human Vaccines & Immunotherapeutics
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies.
Shahrier Hossain, Giada Bianchi
doaj   +1 more source

Early Impact of Childhood Opportunity on Neurocognitive Outcomes in Sickle Cell Disease

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neurocognitive impairment is a well‐recognized complication of sickle cell disease (SCD) that begins early in childhood and persists across development. While cerebrovascular injury contributes substantially to risk, neurocognitive deficits are also observed in children without overt or silent cerebral infarctions, suggesting ...
Julia E. LaMotte, Hannah Koch, Olivia A. Coughlin, Jillian R. Bouck, Allie Carter, Seethal A. Jacob   +5 more
wiley   +1 more source

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease [PDF]

Proceedings of the National Academy of Sciences, 2004
Although there is considerable evidence that a subpopulation of regulatory CD4 + CD25 + T cells can suppress the response of autoreactive T cells, the underlying molecular mechanism is not understood. We find that transmission of a suppressive signal by
Silke, Paust, Linrong, Lu, Nami, McCarty, Harvey, Cantor   +3 more
openaire   +2 more sources

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

Journal of Translational Medicine, 2023
Background Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer.
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, Giada Juli, Craig A. Hokanson, Tatjana Odineca, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Antonia Mancuso, Nicoletta Staropoli, Basilio Caparello, Maria Cerra, Giuseppe Nisticò, Pierosandro Tagliaferri, Roberto Crea, Daniele Caracciolo, Pierfrancesco Tassone   +17 more
doaj   +1 more source

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control

Journal for ImmunoTherapy of Cancer, 2023
Background Cancer immunotherapies can produce complete therapeutic responses, however, outcomes in ovarian cancer (OC) are modest. While adoptive T-cell transfer (ACT) has been evaluated in OC, durable effects are rare.
Kunle Odunsi, Takemasa Tsuji, Mark Long, Danuta Kozbor, Scott I Abrams, Emese Zsiros, A J Robert McGray, Jessie L Chiello, Kathryn Maraszek, Nicole Gaulin, Spencer R Rosario, Suzanne M Hess   +11 more
doaj   +1 more source

Ironic Medications: A Narrative‐Based Psycho‐Educational Intervention to Explore Patient–Provider Communication in Adolescents With Haematological Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa, Elena Pagani Bagliacca, Selena Russo, Giulia Rampoldi, Maria Grazia Strepparava, Adriana Cristina Balduzzi, Andrea Biondi, Marco Spinelli   +7 more
wiley   +1 more source